Cambridge Investment Research Advisors
CHRS icon

Cambridge Investment Research Advisors’s Coherus Oncology CHRS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73K Buy
52,376
+8,800
+20% +$14.4K ﹤0.01% 3687
2026
Q1 		$74K Sell
43,576
-103
-0.2% -$183 ﹤0.01% 3819
2025
Q4 		$62K Sell
43,679
-6,344
-13% -$9.24K ﹤0.01% 3741
2025
Q3 		$82K Buy
50,023
+1,250
+3% +$1.39K ﹤0.01% 3609
2025
Q2 		$36K Sell
48,773
-3,000
-6% -$2.59K ﹤0.01% 3560
2025
Q1 		$42K Buy
51,773
+3,677
+8% +$4.23K ﹤0.01% 3420
2024
Q4 		$66K Buy
48,096
+32,300
+204% +$36.2K ﹤0.01% 3358
2024
Q3 		$16K Sell
15,796
-3,789
-19% -$5.2K ﹤0.01% 3376
2024
Q2 		$34K Sell
19,585
-5,058
-21% -$10.2K ﹤0.01% 3244
2024
Q1 		$59K Sell
24,643
-180,500
-88% -$444K ﹤0.01% 3201
2023
Q4 		$683K Buy
205,143
+182,061
+789% +$488K ﹤0.01% 1933
2023
Q3 		$86K Buy
23,082
+1,404
+6% +$6.49K ﹤0.01% 2979
2023
Q2 		$93K Hold
21,678
– – ﹤0.01% 3012
2023
Q1 		$148K Buy
21,678
+4,700
+28% +$36.5K ﹤0.01% 2904
2022
Q4 		$134K Buy
16,978
+1,800
+12% +$13.8K ﹤0.01% 2856
2022
Q3 		$146K Sell
15,178
-400
-3% -$4.05K ﹤0.01% 2788
2022
Q2 		$113K Hold
15,578
– – ﹤0.01% 2846
2022
Q1 		$201K Hold
15,578
– – ﹤0.01% 2871
2021
Q4 		$249K Sell
15,578
-1,800
-10% -$31.5K ﹤0.01% 2696
2021
Q3 		$279K Sell
17,378
-200
-1% -$2.93K ﹤0.01% 2523
2021
Q2 		$243K Buy
+17,578
New +$249K ﹤0.01% 2649

Other funds holding CHRS

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Cambridge Investment Research Advisors's CHRS Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Coherus Oncology (CHRS) stake by 20% in Q2 2026, buying an estimated $14.4K and bringing the position to 52,376 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #3687.

Cambridge Investment Research Advisors first reported a position in CHRS in Q2 2021 and has held it in 21 quarters since. The position peaked at $683K in Q4 2023. 21 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Cambridge Investment Research Advisors held 52,376 shares of Coherus Oncology worth $73K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 8,800 Coherus Oncology shares in Q2 2026, an estimated $14.4K.
  • Coherus Oncology made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3687 holding.
  • Cambridge Investment Research Advisors first reported a position in Coherus Oncology in Q2 2021 and has held it in 21 quarters since.
  • Cambridge Investment Research Advisors's Coherus Oncology position peaked at $683K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.